A Case Report of an Advanced Stage Gastrointestinal Stromal Tumor Successfully Treated by Surgery and Imatinib

Ashraf Saad Meligy a*, Ashraf ALakkad b, Fadi Bassam Almahameed a and Aref Chehal c

aDepartment of General Surgery, Madinat Zayed Hospital, AL Dhafra Region, UAE.
bDepartment of Internal Medicine, Madinat Zayed Hospital, AL Dhafra Region, UAE.
cOncology and Hematology Department, Sheikh Shakhbout Medical City, Abu Dhabi, UAE.

ABSTRACT

Background: The most prevalent gastrointestinal sarcoma is a gastrointestinal stromal tumor. It is frequently misdiagnosed due to its indolent symptoms, which only manifest at an advanced and potentially incurable stage.

Case Report: This case report is that of a recent case of a GIST of gastric origin. It discusses the case of a 56-year-old, non-smoking male with no comorbidities who presented to the emergency department with severe colicky intermittent abdominal pain that had occurred over the past three days, approximately three years ago. On September 3, 2019, the patient underwent laparotomy in which a mass and related small bowel segment (the part of the omentum) was removed. Later, the pathology profile revealed a neoplasm of the small bowel-ileum, Gastrointestinal stromal tumor (GIST) with a high-risk tumor of stage 4 with no recorded nodular involvement and no recorded metastasis pT4 pNx pMx but with clear margins. Moreover, the tumor markers KIT (CD117), CD34, and DOG1 (ANO1) were found to be positive. Ki67 was noted up to 35%. However, S-100 and SMA were found to be negative. On gross examination, the lesion's greatest dimension was 11 cm, and other dimensions were 9x6 cm. The tumor had a spindle-shaped morphology. On the basis of these laboratory findings and pathology profile, the patient's diagnosis was a Gastrointestinal Stromal Tumor.
tumor that was managed via surgery. At that time, the patient was also prescribed Imatinib 400 mg. It has been three years since then, our patient is still alive, and no cancer recurrence has been reported yet.

**Conclusion:** This case report revealed that interventional radiology's early engagement with the surgical procedure was the cornerstone of our patient's effective treatment and should be investigated at different stages of the gastrointestinal tumor.

**Keywords:** Gastrointestinal stromal tumor; GIST; c-Kit; small intestine; imatinib.

**1. INTRODUCTION**

In the United States, gastrointestinal stromal tumor (GIST) has an estimated prevalence of 3,000–4,000 cases per year, making it the most prevalent primary mesenchymal gastrointestinal tumor in the country [1,2]. GISTs are believed to originate from interstitial cells of Cajal (ICC) or their stem cell predecessors, which are generally found in the intestine's autonomic nervous system [3]. ICC functions as a pacemaker in regulating motility [4]. Additionally, GIST has been shown to affect males (55%) more frequently than women with median age of (55–60 years) [5].

Furthermore, GIST is a rare tumor that requires a high index of suspicion for its diagnosis [6,7]. With the current radiologic choices available, there is no one procedure with 100% diagnostic certainty [8]. In contrast, computed tomography (CT) angiography provides the ability to pinpoint the bleeding. Hence, an early diagnosis can be made, resulting in a better prognosis [9].

Additionally, according to previous studies, approximately 40–70% of GISTs originate in the stomach, 20–40% in the small intestine, and less than 10% in the rectum, colon, and esophagus [10]. Those are known as extra-gastrointestinal stromal tumors (eGIST) and typically behave aggressively [11]. On the other hand, the retroperitoneum, uterus, and mesentery are examples of extraintestinal sites where GISTs can grow [9]. The prognosis of GIST tumors depends on the location, mitotic rate, tumor size, tumor rupture, lymph node involvement, and molecular mutations [12]. For example, a large study investigated 5,138 adults with GISTs. According to this research, nodal involvement was observed in around 5% of patients and was linked with lower cancer-specific and overall survival [13]. On the other hand, another research showed that young patients presenting GIST with lymph node involvement due to mutations in succinate dehydrogenase had a less aggressive disease and a more favorable prognosis than adults with nodal involvement [12].

Moreover, surgical excision has been the cornerstone of the treatment of GIST for many years. But unfortunately, up to 50% of patients have experienced tumor recurrence over the first five years, which indicates that the results of surgery alone have been insufficient [14]. Additionally, radiation therapy and traditional postoperative chemotherapy have failed to work effectively in the case of GIST [15,16]. On the other hand, the treatment of GIST has been revolutionized by the introduction of small-molecule kinase inhibitors that specifically target the underlying pathogenic mutant kinase. However, recently published cases demonstrate the formation of tumor clones that are resistant to these medications, which limits their potential for long-term success [17]. Therefore, we must find new advanced treatment options to improve the survival of GIST patients. This case report discusses the case of a 56-year-old male who suffered from stage IIIB high-grade small bowel GIST, T4N0, status post-surgery in 2019 and who has been successfully treated through surgery and Imatinib 400 mg as no recurrence was reported in the last three years.

**2. CASE PRESENTATION**

This is a recent case of a GIST of gastric origin. A 56-year-old, non-smoking male with no comorbidities was presented to the emergency department with severe colicky intermittent abdominal pain that lasted for the past three days, approximately three years ago. The patient had a significant medical history. He previously underwent an open appendectomy in 1980, a lap cholecystectomy in 2013, and a parathyroid adenoma (left inferior) excision in 2018. However, there were no associated complaints of any hematological or chronic disorder. On September 3, 2019, the CT abdomen showed a heterogeneous lobulated mass with central necrosis related to small bowel with a size of 16.3x11.8x7.5 cm. The patient underwent a laparotomy during which the mass and related
small bowel segment (the part of the omentum) was removed. During the operation, the small bowel segment was found to be severely encased by the tumor, but not obstructed. Additionally, a resection anastomosis of the small intestine was performed. At this time, the patient had gained full recovery and was discharged from the hospital on September 7, 2019. Histopathological testing was performed and indicated negative margins of resection and GIST tumor of high risk with spindle-shaped cells (stage IIIB). The pathology profile revealed a neoplasm of the small bowel—ileum, resection, Gastrointestinal stromal tumor (GIST), Spindle cell type, and high-risk tumor of staging pT4 pNxMx, but with clear margins. The pathology profile showed negative margins and GIST tumor of high risk with spindle-shaped cells (stage IIIB). The pathology profile revealed a neoplasm of the small bowel—ileum, resection, Gastrointestinal stromal tumor (GIST), Spindle cell type, and high-risk tumor of staging pT4 pNxMx, but with clear margins.

Furthermore, later, a resection of a small intestine segment and an omentectomy were performed. On gross examination, the lesion’s greatest dimension was 11 cm, and other dimensions were 9x6 cm. The tumor type was a gastrointestinal stromal tumor and had a spindle-shaped morphology. There was focally seen necrosis. Additionally, the Mitotic rate was 15 per 50 high power fields, and the resection margins were negative for GIST.

### Table 1. Microscopic description

<table>
<thead>
<tr>
<th>Tumor Site</th>
<th>Small intestine</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tumor Size</td>
<td>Greatest dimension: 11 cm</td>
</tr>
<tr>
<td></td>
<td>Other dimensions: 9x6 cm</td>
</tr>
<tr>
<td>Tumor Focality</td>
<td>Unifocal</td>
</tr>
<tr>
<td>Tumor type</td>
<td>Gastrointestinal stromal tumor</td>
</tr>
<tr>
<td>GIST Subtype</td>
<td>Spindle cell</td>
</tr>
<tr>
<td>Necrosis</td>
<td>Focally seen</td>
</tr>
<tr>
<td>Mitotic Rate</td>
<td>15/50 HPF</td>
</tr>
<tr>
<td>Histologic Grade</td>
<td>G2 High grade; mitotic rate &gt;5/50 HPF</td>
</tr>
<tr>
<td>Risk Assessment</td>
<td>High risk</td>
</tr>
<tr>
<td>Margins</td>
<td>Negative for GIST (3 cm from one surgical end and 2 cm from another surgical end)</td>
</tr>
</tbody>
</table>

### Table 2. Immunohistological results

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>KIT (CD117)</td>
<td>Positive</td>
</tr>
<tr>
<td>DOG1 (ANO1)</td>
<td>Positive</td>
</tr>
<tr>
<td>CD34</td>
<td>Positive</td>
</tr>
<tr>
<td>S-100</td>
<td>Negative</td>
</tr>
<tr>
<td>SMA</td>
<td>Negative</td>
</tr>
<tr>
<td>Ki67</td>
<td>35%</td>
</tr>
</tbody>
</table>

These findings confirmed the diagnosis of a gastrointestinal stromal tumor. Based on his diagnosis, the patient was asked to visit the Oncology department. Therefore, he first went to the oncology department on September 18, 2019. At this time, the patient had been prescribed Imatinib 400 mg for three years and was asked to visit Mafraq Hospital’s Oncology department for a follow-up. He has been on continuous follow-up for three years. Now, on September 9, 2022, in SSMC, he underwent a positron emission tomography scan which showed no recurrence.

### 3. DISCUSSION

A gastrointestinal stromal tumor can arise anywhere in the gastrointestinal tract [18]. It is typically a submucosal lesion with endophytic growth [19]. In addition, it manifests exophytically [20]. According to previous studies, this kind of tumor has been reported to range from 1 to 40 cm in diameter [21]. Additionally, between fifty and seventy-five percent of these originate in the stomach, twenty percent in the small intestine, and less frequently, in the rectum and colon [22]. In our case, the primary tumor site was the small intestine, and the tumor’s maximum dimension was 11 cm.

Additionally, studies indicate that although abdominal ultrasonography is typically the first imaging test performed on a patient with abdominal pain or a mass, the tumor identified is frequently so enormous that the organ of origin cannot be determined [23]. The ultrasonography generally reveals the existence of a massive mass, frequently occupying the abdomen, with heterogeneous reflectivity and frequent necrosis [24]. On the other hand, CT and pathological profiles set the foundation for the diagnosis and staging in the majority of patients [24]. The CT examination will typically provide a rapid and reproducible evaluation of the primary tumor’s size and connection to other structures.

Regional Lymph Nodes (pN): Not applicable
Distant Metastasis (pM): Not applicable

### 2.1 Pathologic Staging

Primary Tumor (pT): pT4: Tumor more than 10 cm in greatest dimensions
Variable levels of necrosis are typically observed in the mass. In our case, the CT abdomen showed a heterogeneous lobulated mass with central necrosis related to the small bowel and measuring 16.3x11.8x7.5 cm.

Furthermore, surgery can be the best option for patients with gastrointestinal cancer. The treatment has a curative goal of operational excision with a clean margin, R0. Additionally, the prognosis of the patient depends on the risk factors associated with the tumor's size and mitotic activity [25]. Tumors greater than 5 to 10 cm in size, with a mitotic count greater than 10/50 HPF, carry a significant risk of malignant potential and recurrence. In these high-risk groups, recurrence rates can exceed 80% [26]. Moreover, according to Fletcher's Risk Factors, 62.5% of high-risk group cases had recurrence or metastasis [27]. Our patient was also at high risk, and cancer had a mitotic activity of 10/50 HPF. However, in his case, after surgery and imatinib therapy, no recurrence has been reported up until now.
Moreover, since the introduction of Imatinib mesylate in 2000, targeted molecular therapy has made significant strides in the care of patients with operated GIST without clean margins, unresectable tumors, or recurrences. In the past few years, this medication and the recently introduced Sunitinib have been utilized with encouraging results as adjuvant and neoadjuvant therapy [28]. The FDA approved the medicine for the treatment of metastatic GIST in 2001, and in 2008 for the prevention of recurrences in operated GIST in intermediate and high-risk patients [29].

Imatinib mesylate is a multitargeted inhibitor of “c-KIT,” “PDGF-R,” and “c-ABL” that inhibits T-cell proliferation. Experts suggested that Imatinib inhibits signal transmission by binding preferentially to ATP-binding sites on “c-KIT proto-oncogene product,” Abelson Kinase (c-ABL), and “platelet-derived growth factor receptor” (PDGF-R) [30]. The use of adjuvant Imatinib mesylate has effectively boosted both overall survival (OS) and progression-free survival in cancer patients [29]. Our patient was also given Imatinib, and favorable outcomes were noted as he is alive and no recurrence has been reported so far.

4. CONCLUSION

GIST is a life-threatening condition. Despite surgery and neoadjuvant therapy, it continues to severely affect patients’ mortality and healthcare. Immunohistochemical staining and CT scan are valuable diagnostic tools for GISTs. This case report suggests that interventional radiology’s early involvement with the surgical procedure was the cornerstone of our patient’s successful therapy. An evaluation of how early diagnoses can be made or when early surgery should be performed requires additional research.

CONSENT

As per international standard or university standard, patients’ written consent has been collected and preserved by the author(s).

ETHICAL APPROVAL

As per international standard or university standard written ethical approval has been collected and preserved by the author(s).

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES


© 2022 Meligy et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:
The peer review history for this paper can be accessed here:
https://www.sdiarticle5.com/review-history/92678